Capricor Therapeutics (NASDAQ:CAPR) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04), FiscalAI reports.

Here are the key takeaways from Capricor Therapeutics’ conference call:

• Capricor said the deramiocel BLA remains under active FDA review with a PDUFA target date of August 22, 2026, and management expects labeling discussions in the near term.
• Management highlighted strong HOPE-3 results, including achievement of the primary PUL v2.0 endpoint, significant secondary endpoints, and encouraging cardiac data that they believe support deramiocel for DMD-associated cardiomyopathy.
• The company emphasized a favorable safety profile, citing more than 800 IV infusions across studies and up to five years of open-label extension data in some patients.
• Capricor announced it has filed suit against NS Pharma and Nippon Shinyaku seeking rescission of the distribution agreement and a preliminary injunction, arguing the current pricing structure would make broad reimbursement and patient access economically unworkable.
• The company said it is building commercial readiness and manufacturing capacity, with its San Diego facility already through FDA pre-license inspection and positioned for an initial launch, while also hiring key commercial leaders and preparing for possible self-distribution.

Capricor Therapeutics Stock Performance

NASDAQ:CAPR traded down $0.38 during mid-day trading on Tuesday, reaching $31.52. 1,055,184 shares of the company’s stock were exchanged, compared to its average volume of 1,285,195. Capricor Therapeutics has a one year low of $4.30 and a one year high of $40.37. The firm has a market capitalization of $1.82 billion, a PE ratio of -13.95 and a beta of 0.48. The business’s fifty day simple moving average is $31.57 and its two-hundred day simple moving average is $23.69.

Wall Street Analysts Forecast Growth

CAPR has been the topic of several research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. B. Riley Financial increased their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.09.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00. Following the sale, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. This represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 172,529 shares of company stock worth $5,302,440. 9.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently bought and sold shares of CAPR. Suvretta Capital Management LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $51,533,000. Tang Capital Management LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $49,062,000. RA Capital Management L.P. acquired a new stake in Capricor Therapeutics during the fourth quarter worth about $43,516,000. Darwin Global Management Ltd. acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $23,168,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $10,188,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.